Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Synthesis method of 6-(dibromomethyl)-2-methylquinazoline-4(3H)-ketone

A technology of dimethylquinazoline and methylquinazoline is applied in the field of synthesis technology of pharmaceutical intermediates and achieves the effects of high yield, convenient operation and improved solubility

Active Publication Date: 2020-11-27
HONGGUAN BIO PHARMA CO LTD
View PDF2 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

There is no synthetic route of the compound reported in the literature at present

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Synthesis method of 6-(dibromomethyl)-2-methylquinazoline-4(3H)-ketone
  • Synthesis method of 6-(dibromomethyl)-2-methylquinazoline-4(3H)-ketone
  • Synthesis method of 6-(dibromomethyl)-2-methylquinazoline-4(3H)-ketone

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0035] The first step: the synthesis of tert-butyl (2,6-dimethylquinazolin-4-yl) formate (2)

[0036] Take a 500mL three-necked flask, add 2,6-dimethylquinazolin-4(3H)-one (1) (10g, 57.40mmol), add anhydrous THF (300mL) and lower the temperature to within 10°C under nitrogen protection, then divide Sodium hydride (11.48 g, 287.00 mmol) was added in portions. After the addition, remove the ice bath, slowly rise to room temperature, add Boc 2 O (15.03g, 68.88mmol), then the temperature was raised to 50-60°C and the reaction was stirred for 3 hours, and the reaction was complete as detected by TLC. The system was cooled down to 0-10°C and quenched with water, then extracted with ethyl acetate, the organic phases were combined, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to remove the solvent. Add silica gel to mix the sample, and purify by column chromatography (eluent: petroleum ether: ethyl acetate=20:1) to obtain te...

Embodiment 2

[0042] The first step: the synthesis of tert-butyl (2,6-dimethylquinazolin-4-yl) formate (2)

[0043] Take a 500mL three-necked flask, add 2,6-dimethylquinazolin-4(3H)-one (1) (10g, 57.40mmol), add anhydrous THF (300mL) and lower the temperature to below -10°C under nitrogen protection. Add LDA (2mol / L, 34mL, 68.88mmol) and keep the reaction for about 0.5 hours. After the addition, it was slowly raised to room temperature, and Boc was added 2O (15.03g, 68.88mmol), then the temperature was raised to 50-60°C and the reaction was stirred for 3 hours, and the reaction was complete as detected by TLC. Cool the system down to 0-10°C and add water to quench it, add ethyl acetate to extract, combine the organic phases, dry over anhydrous sodium sulfate, filter, concentrate the filtrate under reduced pressure to remove the solvent, add silica gel to mix the sample, and purify by column chromatography (eluent: Petroleum ether: ethyl acetate = 20:1) to obtain tert-butyl (2,6-dimethylqu...

Embodiment 3

[0049] The first step: the synthesis of tert-butyl (2,6-dimethylquinazolin-4-yl) formate (2)

[0050] In a 250mL reaction flask, add DMF (60mL), add 2,6-dimethylquinazolin-4(3H)-one (1) (2.00g, 11.48mmol) under stirring, nitrogen protection, and then add hydrogen in sequence Potassium oxide (3.21g, 57.40mmol), Boc 2 O (3.01g, 13.78mmol), then heated up to 50-60°C and stirred for 2-3h, TLC reaction was complete, then cooled to 0-10°C, filtered to remove inorganic salts, added water and ethyl acetate to extract layers, combined The organic phase was dried and filtered using anhydrous sodium sulfate, the filtrate was concentrated under reduced pressure to remove the solvent, the sample was mixed with silica gel, and purified by column chromatography (eluent: petroleum ether: ethyl acetate = 20:1) to obtain compound 2 (yield 2.52g , yield 80.0%).

[0051] The second step: the synthesis of tert-butyl (6-(dibromomethyl)-2-methylquinazolin-4-yl) formate (3) in the 100mL reaction fl...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to a synthesis method of an important medical intermediate 6-(dibromomethyl)-2-methylquinazoline-4(3H)-ketone. According to the invention, 2, 6-dimethylquinazoline-4(3H)-ketone (1) is used as an initial raw material, and Boc protective group is added under alkaline conditions to prepare the compound (2), so that the polarity of 2, 6-dimethylquinazoline-4(3H)-ketone is effectively reduced, and the solubility is improved, and the bromination probability of 2-methyl is reduced by increasing steric effect and electronic effect; bromination reaction is carried out on the compound (2) to obtain a 6-methyl dibrominated product (3) with high selectivity; and finally, the protecting group is removed through an acidic reagent to obtain the high-purity 6-(dibromomethyl)-2-methylquinazoline-4(3H)-ketone. The synthesis method of the 6-(dibromomethyl)-2-methylquinazoline-4(3H)-ketone is simple in process route, convenient to operate, good in selectivity and high in yield.

Description

technical field [0001] The invention relates to the technical field of medicine preparation, in particular to a synthesis process of a medicine intermediate. Background technique [0002] Raltitrexed, a quinazoline folate analogue, is a novel water-soluble inhibitor of thymidylate synthase, which can cause DNA fragmentation and cell death by inhibiting thymidylate synthase. Compared with 5-fluorouracil, raltitrexed has stronger selectivity, and can replace fluorouracil in the treatment of advanced colorectal cancer, and has become the first-line drug for the treatment of advanced colorectal cancer. [0003] Raltitrexed was developed and created by the British Zeneca Pharmaceutical Company. It was first launched in the UK in 1996. The trade name is Tomudex, and the chemical name is: N-[5-[N-methyl-N-(2-methyl-4-oxo Substitute-3,4-dihydroquinazoline-6-methyl)amino]thiophene-2-formyl]-L-glutamic acid, the structural formula is: [0004] [0005] A key intermediate is invol...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C07D239/90
CPCC07D239/90Y02P20/55
Inventor 朱金龙于学彬徐磊杨鑫杰张新丽朱渝峰张旭东
Owner HONGGUAN BIO PHARMA CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com